Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 6, Issue 1, 2011, Pages 64-70

  Scagliotti, Giorgio ^a   Brodowicz, Thomas ^b,c   Shepherd, Frances A ^d   Zielinski, Christoph ^b,c   Vansteenkiste, Johan ^e   Manegold, Christian ^f   Simms, Lorinda ^g   Fossella, Frank ^h   Sugarman, Katherine ^g   Belani, Chandra P ⁱ  

^a UNIVERSITY OF TURIN   (Italy)

^b Central European Cooperative Oncology Group Austria   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g ELI LILLY AND COMPANY   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ PENN STATE CANCER INSTITUTE   (United States)

Author keywords

Adenocarcinoma; Histology; Large cell carcinoma; Non small cell lung cancer; Nonsquamous; Pemetrexed; Squamous cell carcinoma; Thymidylate synthase

Indexed keywords

CISPLATIN; DOCETAXEL; GEMCITABINE; PEMETREXED; PLACEBO;

ADULT; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PATIENT CARE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; VOMITING;

EID: 78651066494     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181f7c6d4     Document Type: Article

References (35)

1. Stanley KE. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 1980;65:25-32.
2. Jiroutek M, Johnson D, Blum R, et al. Prognostic factors in advanced non-small cell lung cancer (NSCLC): analysis of Eastern Cooperative Oncology Group (ECOG) trials from 1981-1992. Proc Am Soc Clin Oncol 1998;17:Abstract 1774.
3. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 2002;122:1037-1057.
4. Ginsberg RJ, Vokes EE, Rosenzweig K. Non-small cell lung cancer. In VT DeVita Jr, S Hellman, SA Rosenberg (Eds.), Cancer Principles and Practice of Oncology, 6th Ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2001. Pp. 925-983.
5. Scagliotti GV, de Marinis F, Rinaldi M, et al. The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial. J Thorac Oncol 2009;4:1568-1571.
6. Schiller JH, Harrington D, Belani CP, et al. Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98.
7. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy- naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.
8. Einhorn LH. First-line chemotherapy for non-small-cell lung cancer: is there a superior regimen based on histology? J Clin Oncol 2008;26: 3485-3486.
9. Hirsch FR, Spreafico A, Novello S, et al. The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review. J Thorac Oncol 2008;3:1468-1481.
10. Belani CP, Brodowicz T, Ciuleanu T, et al. Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: a randomized phase III study in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2009;27:Abstract CRA8000.
11. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-2191.
12. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer- molecular and clinical predictors of outcome. N Engl J Med 2005;353: 133-144.
13. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers-a different disease. Nat Rev Cancer 2007;7:778-790.
14. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132.
15. Peng G, Zinner RG, Wang Y, et al. Comparison of patient outcomes stratified by histology among pemetrexed (P)-treated patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC) in two phase II trials. J Clin Oncol 2008;26(Suppl):Abstract 8096.
16. Kubota K, Niho S, Enatsu S, et al. Efficacy differences of pemetrexed by histology in pretreated patients with stage IIIB/IV non-small cell lung cancer: review of results from an open-label randomized phase II study. J Thorac Oncol 2009;4:1530-1536.
17. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597.
18. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist 2009;14:253-263.
19. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009;374:1432-1440.
20. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992;10:239-253.
21. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
23. Pujol JL, Breton JL, Gervais R, et al. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol 2005;16:602-610.
24. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355: 2542-2550.
25. Brodowicz T, Krzakowski M, Zwitter M, et al. Central European Cooperative Oncology Group CECOG. Cisplatin and gemcitabine firstline chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 2006;52:155-163.
26. Scagliotti GV, Brodowicz T, Shepherd FA, et al. Pemetrexed is more effective in patients with nonsquamous non-small cell lung cancer (NSCLC) histology: an analysis of three large, randomized, phase III trials. J Thorac Oncol 2009;4:Abstract B2.6.
27. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366: 1527-1537.
28. Grønberg BH, Bremnes RM, Fløtten O, et al. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2009;27:3217-3224.
29. Shih C, Chen VJ, Gossett LS, et al. LY231514, a pyrrolo[2,3-d]pyrimidine- based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997;57:1116-1123.
30. Mendelsohn LG, Shih C, Chen VJ, et al. Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis. Semin Oncol 1999;26:42-47.
31. Schultz RM, Chen VJ, Bewley JR, et al. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs. Semin Oncol 1999; 26:68-73.
32. Sigmond J, Backus HH, Wouters D, et al. Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. Biochem Pharmacol 2003;66:431-438.
33. Giovannetti E, Mey V, Nannizzi S, et al. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 2005;68:110-118.
34. Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006;107:1589-1596.
35. Hanauske AR, Eismann U, Oberschmidt O, et al. In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression. Invest New Drugs 2007;25:417-423.